Outcomes in patients with atrial fibrillation undergoing coronary artery stenting with a low-moderate CHA2DS2VASc score: do they need anticoagulation?
| Autor: | B. Garcia Del Blanco, Angel Cequier, David Garcia-Dorado, Fernando Alfonso, Héctor Bueno, Antonia Sambola, M. Mutuberria Urdaniz, Eduard Bosch, Javier Zueco, José A. Barrabés |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Stent Management of atrial fibrillation Atrial fibrillation medicine.disease Revascularization Internal medicine CHA2DS2–VASc score Conventional PCI Cardiology Medicine Myocardial infarction Cardiology and Cardiovascular Medicine business Adverse effect |
| Zdroj: | European Heart Journal. 34:P4093-P4093 |
| ISSN: | 1522-9645 0195-668X |
| Popis: | Background: European Society of Cardiology guidelines for the management of atrial fibrillation (AF) recommend oral anticoagulation (OAC) in patients with CHA2DS2VASc score ≥1. However, these recommendations are not always followed in clinical practice. We assessed the impact of OAC in the particular group of patients with AF, and a low-moderate thromboembolic risk submitted to PCI with stenting (PCI-S), and therefore have an indication for dual antiplatelet therapy (DAPT). Methods: A multicenter study was conducted from 2007 to 2011 to identify patients with non-valvular AF and low-moderate thromboembolism risk (CHA2DS2VASc |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|